Today in a significant departure from our usual style where we largely focus on technical side of story, we will be more focused towards fundamental side of the story. This post is about a small cap pharma company with market cap of around 500 Cr. The product portfolio is impressive. A Debt free, Consistently Dividend …

When big money starts moving in, there is not much left other than stock making some crazy moves and since most individual investors are still in disbelief so they are not positioned yet and soon they will rush in. Sector doing this for few weeks is Information Technology. When you see most of the stocks …

The mortality rate of small caps and micro caps is way too high for most of the individual investors to make consistent wealth from the space. They, if managing things alone, are better off focusing on more liquid, bigger and proven names. That of course will result in subdued returns. The stories often told to …

Pharma, Chemicals, Technology, IT, Platform & Agri businesses have been doing great right after the bottom was made in last week of March, 2020. This small cap pharma after doubling in last 8 months has become mid cap and in next reclassification of Jan 2021, it will be classified as such. The company has been …

Claiming that regulatory changes do not affect the stocks is either out of naivety or plain lying. Under that backdrop, new circular by SEBI for multi cap funds to invest minimum 25% of funds in mid caps and 25% in small caps bodes well for market participants. We will talk about a stock which has …